AA-IPRAVENT 250 MCG
IPRATROPIUM BROMIDE : 250 MCG · DIN 02126222 · AA PHARMA INC
Health Canada status: MARKETED
What is AA-IPRAVENT?
AA-IPRAVENT 250 MCG contains IPRATROPIUM BROMIDE : 250 MCG. It is listed in the Health Canada Drug Product Database under DIN 02126222, held by AA PHARMA INC, supplied as SOLUTION for INHALATION administration. Health Canada currently lists it as marketed, status dated 28-Mar-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AA-IPRAVENT used for?
Treatment of bronchospasm associated with acute exacerbations of COPD (bronchitis/emphysema) and acute severe asthma (when used with a beta2-agonist).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02126222 |
|---|---|
| Brand name | AA-IPRAVENT |
| Generic / active ingredient | IPRATROPIUM BROMIDE : 250 MCG |
| Manufacturer | AA PHARMA INC |
| Strength | 250 MCG |
| Dosage form | SOLUTION |
| Route of administration | INHALATION |
| Schedule | Prescription |
| ATC code | R03BB01 IPRATROPIUM BROMIDE |
| AHFS class | 12:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Mar-2024 |
| Original market date | 1994-12-31 00:00:00 |
How is it administered?
Adults: 250-500 mcg. Children (5-12 yrs): 125-250 mcg. Repeat every 4-6 hours as necessary. Administer via nebulizer with gas flow (6-10 L/min) over 10-15 minutes. Dilute if volume < 2 mL.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Note: General house standard for solution storage, though specific text section 11 was not fully provided in snippet).
How is it supplied?
20 mL amber glass bottle with screwcap.
Contraindications
History of hypersensitivity to ipratropium bromide, atropine or its derivatives, or any ingredient in the formulation (including benzalkonium chloride and EDTA-disodium).
Warnings and precautions
Risk of paradoxical bronchospasm. Caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Avoid contact with eyes. Not for initial rescue therapy.
What can be used instead?
Other Canadian products sharing ATC code R03BB01 IPRATROPIUM BROMIDE. 8 of 30 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ATROVENT HFA | 20 MCG | METERED-DOSE AEROSOL | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | DIN 02247686 |
| JAMP IPRATROPIUM HFA | 20 MCG | METERED-DOSE AEROSOL | JAMP PHARMA CORPORATION | MARKETED | DIN 02542587 |
| PMS-IPRATROPIUM | 125 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02231135 |
| PMS-IPRATROPIUM | 21 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02239627 |
| PMS-IPRATROPIUM | 250 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02231245 |
| PMS-IPRATROPIUM | 250 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02231244 |
| TEVA-IPRATROPIUM STERINEBS | 250 MCG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02216221 |
| APO-IPRAVENT STERULES | 125 MCG | SOLUTION | APOTEX INC | CANCELLED POST MARKET | DIN 02243827 |
| APO-IPRAVENT STERULES | 250 MCG | SOLUTION | APOTEX INC | CANCELLED POST MARKET | DIN 02231494 |
| ATROVENT | 250 MCG | SOLUTION | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | DIN 00731439 |
Who else supplies IPRATROPIUM BROMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IPRATROPIUM BROMIDE appears in 80 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.